Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on August 24, 2020, covering events occurring on August 21, 2020. The filing reports the appointment of a new Chief Financial Officer and the execution of a related executive employment agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation terms rather than operational financial performance.
Material Changes
The primary material change reported is the appointment of Kerri-Ann Millar as Chief Financial Officer, effective August 21, 2020. Ms. Millar previously served as the Company's Vice President of Finance since May 2018 and Corporate Controller since September 2017.
Management Commentary and Compensation Details
In connection with the appointment, the Company entered into an Executive Employment Agreement with the following terms:
- Base Salary: $325,000 annually.
- Target Bonus: No less than 35% of the Base Salary.
- Stock Options: Grant of 65,000 options vesting over four years in equal semi-annual installments, beginning six months from issuance.
- Restricted Stock Units (RSUs): Grant of 20,000 RSUs, with one-third vesting on the grant date and the balance vesting in two equal annual installments on the first and second anniversaries.
The filing does not contain specific guidance, outlook, risks, or contingencies beyond the standard incorporation of the employment agreement exhibit.
Key Facts for Investor Verification
- Verify the total equity grant value (65,000 options and 20,000 RSUs) relative to the current share price and dilution impact.
- Confirm the vesting schedule details for the RSUs and options as outlined in Exhibit 10.1.
- Review the Company's recent financial statements (e.g., 10-Q or 10-K) to assess the impact of the new CFO's compensation on future operating expenses.
- Check for any subsequent filings regarding the departure of the previous CFO or interim financial leadership.